Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proline-type fullerene derivative P3 is a water-soluble chemical compound derived from the functionalization of a C60 fullerene core with three carboxy groups and proline moieties. It has been studied for its biological activity in inhibiting adipogenesis (the formation of fat cells) in vitro. Specifically, it suppresses lipid accumulation and the expression of adipocyte-specific genes such as aP2 in preadipocyte cell models by preventing activation of peroxisome proliferator-activated receptor gamma (PPARγ), a key regulator of adipocyte differentiation. Unlike other related derivatives with only two carboxy groups, the tri-carboxylated structure of P3 is critical for its anti-adipogenic effect. The compound has shown potential anti-obesity activity at the cellular level but does not affect upstream regulators like C/EBPδ or C/EBPβ[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on proline-type fullerene derivative P3.